
An announcement from Standard BioTools ( ($LAB) ) is now available. On June 6, 2026, Standard BioTools entered an agreement with Treeline Biosciences and Siri Merger Sub for a merger
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LAB | Standard BioTools | 0.54 | -0.54 | -49.92% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.54 | -49.92% |

An announcement from Standard BioTools ( ($LAB) ) is now available. On June 6, 2026, Standard BioTools entered an agreement with Treeline Biosciences and Siri Merger Sub for a merger

Standard Biotools Inc (LAB) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect Standard Biotools Inc to post earnings of -$0.02 per share.

Standard BioTools ( ($LAB) ) has shared an announcement. On November 3, 2026, ARCHIMED and Standard BioTools completed the sale of Standard BioTools’ Microfluidics business to ARCHIMED. The business began

Standard BioTools ( ($LAB) ) has shared an announcement. On October 5, 2026, Standard BioTools announced that it had entered into a definitive agreement to sell its Microfluidics business to

Standard BioTools (LAB) announced it has entered into a definitive agreement to sell its Microfluidics business to Archimed. Michael Egholm, president and CEO of Standard BioTools, said, “Archimed brings deep

Standard BioTools ( ($LAB) ) has shared an update. On September 30, 2026, Standard BioTools terminated its July 28 agreement to sell its Mass Cytometry business to Multiplex Bio, paying

Standard BioTools (LAB) announced updates in connection with the company’s merger with Treeline Biosciences. Standard BioTools terminated its previously announced agreement to sell its Mass Cytometry Business to Multiplex Bio

Standard BioTools ( ($LAB) ) has issued an announcement. Standard BioTools reported second-quarter 2026 revenue of $20.1 million, down 7.6% year-over-year, with declines across consumables, instruments and services, but improved

Standard Biotools Inc (LAB) is scheduled to report 2nd quarter earnings on 08/05/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Standard Biotools Inc to post earnings

Standard BioTools ( ($LAB) ) has issued an update. On July 24, 2026, Standard BioTools agreed a termination and waiver deal with Illumina under which it received about $30 million
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.